Prior large database studies have observed that, overall, there may be no significant differences in the risk of serious infections between patients with IBD who are treated with vedolizumab and those treated with TNF antagonists.11,25 However, vedolizumab was associated with a lower risk of serious infections compared with TNF antagonists among patients with UC, with no significant difference observed among patients with CD. Here, TNF is linked to inflammatory bowel disease.